Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on November 20, 2006

Hypertension. 2006
Published online before print November 20, 2006, doi: 10.1161/01.HYP.0000251301.12357.ba
A more recent version of this article appeared on January 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
49/1/84    most recent
01.HYP.0000251301.12357.bav1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, P. J.
Right arrow Articles by Rademacher, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, P. J.
Right arrow Articles by Rademacher, T. W.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Risk Pregnancy
Related Collections
Right arrow Secondary prevention
Right arrow Other hypertension
Right arrow Glucose intolerance
Right arrow Other diagnostic testing

Submitted on May 25, 2006
Revised on June 12, 2006

Inositol Phosphoglycan P-Type in Preeclampsia. A Novel Marker?

Philip J. Williams; Khalid Gumaa; Marco Scioscia*; Christopher W. Redman; and Thomas W. Rademacher

From the Department of Molecular Pathology (P.J.W., M.S., T.W.R.), Molecular Medicine Unit, Royal Free and University College Medical School, London, United Kingdom; the College of Medicine and Medical Sciences (K.G.), Arabian Gulf University, Manama, Kingdom of Bahrain; the Department of Obstetrics and Gynaecology (M.S.), University of Bari, Bari, Italy; and the Nuffield Department of Obstetrics and Gynaecology (C.W.R.), University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

* To whom correspondence should be addressed. E-mail: marcoscioscia{at}gmail.com.

Abstract--A state of insulin resistance has been demonstrated in active preeclampsia, and women with clinical evidence of insulin resistance are at higher risk to develop this syndrome during pregnancy. Recently, inositol phosphoglycan P-type, a putative second messenger of insulin action, has been implicated in the pathophysiology of preeclampsia and is increased in the placenta, amniotic fluid, and maternal urine of preeclamptic women compared with normal pregnant women. We report here a case-control study to assess the potential of urinary levels of inositol phosphoglycan P-type as a screening test for preeclampsia. Twenty-seven preeclamptic women and 47 healthy pregnant women were recruited. A polyclonal antibody-based ELISA was developed to detect levels of inositol phosphoglycan P-type in urine. Its content in urinary specimens was found to be 30-fold higher in preeclamptic subjects than control subjects (329.1±21.8 versus 9.2±1.5; P<0.001), with a higher level in all of the preeclamptic cases. For 6 women who developed preeclampsia, >1 gestational date sample of urine was available, and retrospective analysis showed a significant time-related increase of the urinary level of inositol phosphoglycan P-type ≤7 weeks before clinical diagnosis of preeclampsia. Urinary level of inositol phosphoglycan P-type increased after diagnosis indicating a possible pathophysiological threshold level and steeply decreased after delivery.


Key words: preeclampsia • screening test • inositol phosphoglycan • biological marker • insulin resistance




This article has been cited by other articles:


Home page
HypertensionHome page
B. D. LaMarca, J. Gilbert, and J. P. Granger
Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia
Hypertension, April 1, 2008; 51(4): 982 - 988.
[Full Text] [PDF]